Promising management of pazopanib-induced liver toxicity.
Department of Medical Oncology, Radboud University Medical Center , Nijmegen , the Netherlands.
Myrella
M
Vlenterie
Nielka P
NP
van Erp
Winette T A
WT
van der Graaf
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007191:Indazoles; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011239:Prednisolone / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D016879:Salvage Therapy / Q000009:adverse effects / Q000379:methods; D013584:Sarcoma, Synovial / Q000188:drug therapy*; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*
D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib; D011239:Prednisolone